PDCD1 and neoplasm: PD-1 blockade also activates tumorigenic TGFβ signaling in tumor cells that can be targeted by a TGFβ depleting antibody to enhance the immune checkpoint blockade response20, and conversely TGFβ-induced EMT can promote PD-L1 expression21.